{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-23-000005","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.638631+00:00","generated_at":"2026-06-19T11:51:39.183745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Royalty Pharma Q4 Adj Cash Receipts up 96% YoY; guides FY23 $2.375-$2.475B excl. $475M milestone","bullets":["Q4 2022 Adj Cash Receipts $1,064M (+96% YoY); FY 2022 $2,789M (+31%).","Q4 GAAP operating cash flow $570M (+16% YoY); FY $2,144M (+6%).","Announced transactions up to $3.5B in 2022, including $2.0B in upfront payments.","FY 2023 guidance: Adj Cash Receipts $2,375M-$2,475M, underlying growth 4-9% prior to Biohaven payments; excludes potential $475M zavegepant milestone.","In 2023, agreed to provide $500M upfront to Ionis Pharmaceuticals for a new partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-23-000005","json":"https://secwatch.observer/filing/0001802768-23-000005.json","markdown":"https://secwatch.observer/filing/0001802768-23-000005.md","text":"https://secwatch.observer/filing/0001802768-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/0001802768-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/rprx-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:51:39.183745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f5d9932cabdccd423ddae80972c3d1b91367f11","claim":"Royalty Pharma plc updated its the quarter and year ended December 31, 2022 guidance (initiated).","evidence_excerpt":"On February 15, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/0001802768-23-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}